Results 201 to 210 of about 35,569 (305)

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

Mechanisms of Glucagon-Like Peptide 1 Receptor Agonist-Induced Facial Lipodystrophy and a Path Toward Prevention. [PDF]

J Cosmet Dermatol
Kruglikov IL.
europepmc   +1 more source

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This Phase 1b, randomised, double‐blind clinical trial investigated the contribution of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. Materials and Methods Participants were randomised to receive the long‐acting
Tim Heise, Eric Zijlstra, Andrea Mari, William C. Roell, Kieren J. Mather, Axel Haupt, Panagiotis Flevaris, Ran Liao, Laiyi Chua, Charles Harris, Edward J. Pratt   +10 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without Diabetes.

JAMA Netw Open
Xie L, Anazco D, Chancay AH, Mathew MS, Francis JM, Almandoz JP, Messiah SE.   +6 more
europepmc   +1 more source

Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Metabolism and the Expression of Insulin Receptor Substrate 1 in an Osteoporotic Rat Model. [PDF]

Int J Endocrinol
Ye Y, He YL, He J, Yang DY, Xia N.
europepmc   +1 more source

Association Between SGLT2 Inhibitors and DPP‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim, Yun Kyung Cho, Mi‐Sook Kim, Joongyub Lee, Seonghae Kim, Bo Ram Yang   +5 more
wiley   +1 more source

The Glucagon-like Peptide-1 Receptor Agonist Era and Its Influence on Body-Contouring Referrals After Weight Loss in Appalachia. [PDF]

Plast Reconstr Surg Glob Open
Rahimpour A, Stuart I, Hyde JH, Roberts-Moore K, Price KR, Keefer JD, Persily A, Bown P, Barry R.   +8 more
europepmc   +1 more source

Effects of Calorie Restriction With and Without Strength, Endurance or Mixed Training on Fat‐Free and Skeletal Muscle Mass in Overweight or Obese Individuals—A Systematic Review With Pairwise Meta‐Analysis and Network Meta‐Analysis of Randomized Controlled Studies

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Calorie restriction (CR) reduces both fat mass and fat‐free mass (FFM), particularly skeletal muscle mass (SMM), which is essential for cardiometabolic health and preventing frailty. This study compares CR alone versus CR plus exercise (EX) on FFM and SMM in overweight/obese patients and examines the effects of different training modes ...
Magdalena Deller, Jan Weiershaus, Steffen Held, Christian Brinkmann   +3 more
wiley   +1 more source

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use

Indian Journal of Endocrinology and Metabolism, 2015
Sanjay Kalra, Mallya Ganapathi, Ambrish Mithal   +2 more
doaj   +1 more source

Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial

Yongsheng Cao,1 Jianqin Zhao,2 Yanjuan Ma,2 Shujie Cao,2 Ying Liu2 1Department of Neurology, Sunshine Union Hospital, Weifang, Shandong, People’s Republic of China; 2Department of Endocrinology, Sunshine Union Hospital, Weifang, Shandong, People’s ...
Liu Y, Cao Y, Ma Y, Cao S, Zhao J
core